Last updated: August 10, 2025
Introduction
Patent CN101087752 pertains to a pharmaceutical invention filed in China, aimed at safeguarding specific formulations, methods, or compositions related to a particular drug or therapeutic application. To inform strategic decisions—whether for licensing, research, or competitive intelligence—comprehensive analysis of its scope, claims, and landscape positioning is essential. This detailed review dissects CN101087752's legal scope, assesses its claims' breadth, and maps its patent landscape status within the Chinese and global pharmaceutical domains.
Patent Overview and Filing Context
CN101087752 was filed in China, with publication date recorded as September 25, 2009. Its priority or filing date likely predates this, but the publication provides the basis for legality, scope, and territorial protection. Typically, Chinese pharmaceutical patents at this time target innovative formulations, new uses, or manufacturing methods.
While specific technical details of the patent require presentation of the claims, generally, Chinese patents involve a broad set of claims capturing a core inventive concept, possibly supplemented with narrower dependent claims.
Scope of the Patent
Legal Protection and Territorial Extent
Patent CN101087752 grants exclusive rights within the territory of China, covering:
- Formulations or compositions related to the specified drug.
- Manufacturing processes if claimed.
- Uses or indications if claims specify therapeutic applications.
The scope is defined by explicit claims, which delineate the boundaries of protection. Given Chinese patent law, claims are categorized into independent and dependent claims, influencing the patent's breadth and enforceability.
Claims Analysis
Without access to the full text here, a typical analysis would include:
-
Independent Claims: Usually define the core invention, possibly covering a novel chemical entity, a specific formulation, or a method of manufacture. These are crafted to balance broad coverage with novelty and inventive step.
-
Dependent Claims: Narrower claims that specify particular embodiments, such as specific excipients, dosages, or process steps, serving to fortify the patent against challenges.
Assuming CN101087752 claims a pharmaceutical composition, its scope likely encompasses the active ingredient(s) combined with excipients, specific dosage forms, or manufacturing steps. The most critical element is whether the claims cover:
- Novel compounds or uses: Does the patent claim a new chemical entity or a new therapeutic application?
- Formulation innovations: Are specific formulations claimed, e.g., sustained-release matrices?
- Manufacturing methods: Are novel synthesis or processing techniques included?
Claim Breadth and Patent Strength
The scope's strength hinges on:
- Claim broadness: Overly broad claims may face invalidity challenges if prior art is found; narrowly tailored claims are easier to defend but offer less market exclusivity.
- Novelty and inventive step: The claims must demonstrate non-obviousness over existing Chinese or international art.
In the context of Chinese patent law, patents with well-drafted independent claims that cover a broad class of compounds or formulations generally possess stronger enforcement potential, provided they are novel and inventive.
Patent Landscape for the Technology Area
Position within Chinese Patent Portfolio
- Prevalence of similar patents: The patent landscape within China's pharmaceutical sector reveals a proliferation of patents targeting formulations, compositions, and methods similar to CN101087752.
- Relevant players: Domestic and international competitors, including Chinese biotech firms, multinationals, and research institutes, actively file patents in this space.
Key Related Patents and Prior Art
- Patents filed before CN101087752 likely include earlier formulation technologies, which may influence claims’ novelty.
- Subsequent patents may reference or cite CN101087752, indicating its influence or areas of technological evolution.
Patent Family and Continuation Strategy
- Chinese applicants often file continuation applications or divisionals to extend protection.
- It remains crucial to identify if this patent is part of a broader patent family, including patents in other jurisdictions (e.g., PCT applications or filings in Europe/US), to evaluate global patent strength.
Legal and Enforcement Environment
- The Chinese patent landscape in pharmaceuticals has matured, with increasing enforcement actions and patent invalidation proceedings.
- Patent robustness depends on prosecution history, claim quality, and prior art references.
Competitive Strategies and Implications
- Freedom-to-Operate Analysis: Entry into relevant markets requires analyzing whether CN101087752's claims intersect with existing or future patents.
- Licensing and Partnerships: The patent’s position may be leveraged for licensing negotiations, especially if it covers a core formulation or method.
- Patent Challenges: Competitors may challenge the patent via invalidation proceedings or oppositions, especially if prior art laws are invoked.
Legal Status and Maintenance
- As of the latest available data, CN101087752 remains granted or in maintenance, subject to renewal fees.
- Analyzing patent expiry dates—is usually 20 years from the filing date—can inform timing for market entry or after-expiry strategies.
Conclusion
Patent CN101087752 exemplifies a strategically significant Chinese pharmaceutical patent with claims potentially covering a specific drug formulation or method. Its scope, primarily dictated by its independent claims, defines the extent of protection and enforcesability. The patent landscape reveals ongoing innovation in this domain, with important legal and commercial implications for stakeholders aiming to operate within Chinese pharmaceutical markets.
Key Takeaways
- Scope delineation hinges on the wording of the independent claims; broad claims enhance exclusivity but risk invalidation.
- Landscape positioning indicates CN101087752 is part of an active competitive environment with numerous related patents.
- Strategic implications include evaluating freedom to operate, potential licensing opportunities, and patent enforcement strengths.
- Patent validity depends on maintaining the patent and defending against challenges based on prior art.
- Global relevance requires cross-jurisdictional patent family analysis to safeguard inventions beyond China.
FAQs
-
What is the primary inventive focus of CN101087752?
Without full claim language, the primary focus is presumed to be a pharmaceutical formulation or method of manufacture, designed to improve efficacy, stability, or delivery, within the scope of Chinese patent law.
-
How broad are the claims typically in Chinese pharmaceutical patents like CN101087752?
They can range from broad compositions or methods to narrower, explicitly defined formulations. The actual breadth depends on prosecution strategies and prior art considerations.
-
Can CN101087752 be challenged or invalidated?
Yes. It can be challenged through Chinese patent invalidation procedures, especially if prior art invalidates its novelty or inventive step.
-
What is the strategic value of this patent in the Chinese market?
It offers exclusivity within China, enabling market control, licensing, or blocking competitors if the claims cover core product features.
-
Does this patent have equivalents in other jurisdictions?
Potentially, if filed as part of a broader patent family or via international applications like PCT. Cross-jurisdictional analysis is necessary for global patent strategy.
References
- [1] Chinese Patent Office, CN101087752 Patent Document
- [2] WIPO, PCT Database for related filings
- [3] Chinese Patent Law and Examination Guidelines
